Skip to main content
. 2017 May 17;8(30):49689–49701. doi: 10.18632/oncotarget.17917

Figure 3. Four point mutations in four patients.

Figure 3

(2 ALK: F1174L; BRCA2: K2392N; PHOX2B: F86fs)